Literature DB >> 4066266

Effect of lymphocytapheresis plus cyclophosphamide on the course of a chronic progressive form of multiple sclerosis.

S Ferla, G Meneghetti, S Spartà, M Belloni, G Ongaro.   

Abstract

We report a case of a 16 year old boy with a chronic progressive form of Multiple Sclerosis treated with lymphocytapheresis and a low dose regimen of cyclophosphamide. A progressive improvement in the disability index and slowing of the clinical course were obtained. No side effects were observed. Depletion of lymphocytes and their pharmacological suppression point to their possible role in the induction of an immunoregulation of the disease process.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4066266     DOI： 10.1007/BF02232007

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN： 0392-0461


  10 in total

1.  Astrocytes present myelin basic protein to encephalitogenic T-cell lines.

Authors:  A Fontana; W Fierz; H Wekerle
Journal:  Nature       Date:  1984 Jan 19-25       Impact factor: 49.962

2.  Low T8 antigen density on lymphocytes in active multiple sclerosis.

Authors:  A T Reder; J P Antel; J J Oger; T A McFarland; M Rosenkoetter; B G Arnason
Journal:  Ann Neurol       Date:  1984-08       Impact factor: 10.422

3.  Altered blood T-cell subsets in patients with multiple sclerosis.

Authors:  H L Weiner; D A Hafler; R J Fallis; D Johnson; K A Ault; S L Hauser
Journal:  J Neuroimmunol       Date:  1984-04       Impact factor: 3.478

4.  Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

Authors:  S L Hauser; D M Dawson; J R Lehrich; M F Beal; S V Kevy; R D Propper; J A Mills; H L Weiner
Journal:  N Engl J Med       Date:  1983-01-27       Impact factor: 91.245

5.  Lymphocytapheresis in chronic progressive multiple sclerosis: immunologic and clinical effects.

Authors:  S L Hauser; M Fosburg; S V Kevy; H L Weiner
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

6.  Analysis of T regulator cell surface markers and functional properties in multiple sclerosis.

Authors:  J P Antel; D M Peeples; A T Reder; B G Arnason
Journal:  J Neuroimmunol       Date:  1984-04       Impact factor: 3.478

7.  Phenotypic and functional characterization of T cell clones derived from the cerebrospinal fluid of multiple sclerosis patients.

Authors:  D Santoli; E C Defreitas; M Sandberg-Wollheim; M K Francis; H Koprowski
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

8.  Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages.

Authors:  U Traugott; E L Reinherz; C S Raine
Journal:  J Neuroimmunol       Date:  1983-06       Impact factor: 3.478

9.  Immunoregulatory T-cells and lymphocytotoxic antibodies in active multiple sclerosis: weekly analysis over a six-month period.

Authors:  S L Hauser; E L Reinherz; C J Hoban; S F Schlossman; H L Weiner
Journal:  Ann Neurol       Date:  1983-04       Impact factor: 10.422

10.  Deficit of suppressor T cells in active multiple sclerosis.

Authors:  M A Bach; F Phan-Dinh-Tuy; E Tournier; L Chatenoud; J F Bach; C Martin; J D Degos
Journal:  Lancet       Date:  1980-12-06       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.